“We are incredibly proud of the progress across our entire pipeline this quarter, most notably around our NDA submission for bitopertin in EPP at the end of September and subsequent receipt of the CNPV,” said John Quisel, J.D., Ph.D., Chief Executive Officer and President of Disc. “Achieving this milestone is a strong testament to our team’s commitment to execution and dedication to bringing a potential new treatment option to the EPP patient community. We continue to work with the Agency on their review of our application, and we are furthering our commercial infrastructure in preparation for a potential launch.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine resumed with a Buy at Stifel
- Disc Medicine’s APOLLO Study: A Potential Game-Changer for EPP and XLP Treatment
- Disc Medicine’s New Study on DISC-3405: A Potential Breakthrough for Sickle Cell Disease
- Disc Medicine’s Promising Phase 2 Study on DISC-3405 for Polycythemia Vera
- Disc Medicine’s Promising Anemia Treatment Study: Key Insights for Investors